1q21扩增对初治多发性骨髓瘤患者硼替佐米治疗反应及预后的影响
回顾性分析180例初治多发性骨髓瘤患者,1q21扩增发生率为51.1%。1q为独立不良预后因素,伴1q患者硼替佐米诱导后深度缓解率更高,但长期生存未获益;序贯自体造血干细胞移植可能延长无进展生存。
要点
- 1q21扩增在初治多发性骨髓瘤中发生率为51.1%,常伴del(1p)和IGH重排。
- 1q是PFS和OS的独立不良预后因素(PFS HR=1.910,OS HR=2.353)。
- 伴1q患者硼替佐米诱导后≥VGPR率更高,序贯auto-HSCT可延长PFS。
核心结论
- 1q是初治多发性骨髓瘤患者生存的独立不良预后因素,常伴del(1p)和IGH重排。
- 伴1q患者对硼替佐米为基础的方案反应良好,但该治疗本身未能带来长期生存获益。
- 硼替佐米诱导后序贯auto-HSCT可能改善伴1q患者的生存,提示针对该高危亚组的潜在策略。
- 基因表达谱分析在理解1q高危机制方面需进一步关注。
研究设计与样本
- 回顾性纳入2009年11月至2016年8月180例初治多发性骨髓瘤患者,分析临床特征、细胞遗传学、客观缓解率、PFS和OS。
- 利用公开的R2平台进行基因表达谱分析。
主要发现
- 180例中1q发生率为51.1%(92/180);174例随访完整,其中1q组88例,无1q组86例。
- 1q组与无1q组伴del(1p)发生率分别为27.8%和9.4%(χ²=3.71,P=0.040),伴IGH重排发生率分别为72.2%和57.6%(χ²=4.09,P=0.017)。
- 1q组与无1q组中位PFS分别为15.0个月和20.3个月,中位OS分别为29.4个月和44.0个月,1q组均显著缩短(P=0.029和P=0.038)。
- 多因素分析显示1q为PFS(HR=1.910,95%CI 1.105~3.303,P=0.020)和OS(HR=2.353,95%CI 1.090~5.078,P=0.029)的独立预后因素。
- 91例可评估伴1q患者中,硼替佐米治疗组≥VGPR率为62.1%,非硼替佐米组为40.0%(P=0.032);序贯auto-HSCT组中位PFS为19个月,非移植组为13个月(P=0.048)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Objective: To investigate the effect of 1q21 amplification (1q) on the therapeutic response and prognosis of bortezomib(Btz) in the treatment of newly diagnosed multiple myeloma (MM) patients. Methods: A total of 180 newly diagnosed MM were included for analyses of clinical characteristics, cytogenetics, objective response rate (ORR), progression-free survival (PFS) and overall survival (OS), retrospectively. Gene expression profiling (GEP) was analyzed using publicly available R2 platform. Results: ① In 180 patients, 1q was found in 51.1% cases. Of them, 174 patients had complete follow-up data, including 88 cases with 1q and 86 without 1q (non-1q). ②Incidence of 1q was positively associated with percentage of IGH rearrangement (72.2%, P=0.017) and 1p deletion (1p) (27.8%, P=0.040). ③ The median PFS was 15.0 and 20.3 months for the 1q group and non-1q group, and the median OS was 29.4 and 44.0 months, respectively. Both PFS and OS of 1q group was significantly shorter than those of the non-1q group (P=0.029 and 0.038, respectively). Multivariate analysis further revealed that 1q was an independent prognostic factor for both PFS (HR=1.910, 95% CI 1.105-3.303, P=0.020) and OS (HR=2.353, 95% CI 1.090-5.078, P=0.029). ④ In 91 evaluable cases with 1q, very good partial remission (VGPR) rate was higher after treatment with Btz than those without Btz (62.1% vs 40.0%, P=0.032). Of note, the patients with 1q who received auto-HSCT after induction with Btz had significantly longer PFS than those without auto-HSCT (19 months vs 13 months, P=0.048). ⑤GEP analysis revealed that 1q21 amplification predominantly up-regulated expression of >50% genes within 1q21 region, and also altered expression of 28% genes in chromosome 1 and 10% genes in whole genome, particularly related to DNA repair and cell cycle. Conclusions: 1q is an independent adverse prognostic factor in patients with newly diagnosed MM. It is often associated with 1p deletion and IGH rearrangement. Patients with 1q respond well to Btz-based regimen, but they fail to gain long-term benefit from this treatment itself. However, auto-HSCT following Btz induction might improve survival of patients with 1q, suggesting a potential strategy to treat this high-risk subset of MM. GEP analysis warrants further attention in understanding the mechanisms underlying the high-risk of 1q. 目的: 探讨1q21扩增(简称1q)对硼替佐米(Btz)治疗多发性骨髓瘤(MM)疗效和预后的影响。 方法: 以2009年11月至2016年8月180例初治MM患者为研究对象,比较伴与不伴1q的MM患者的临床特征,分析其对Btz疗效及患者预后的影响,并通过R2分析平台,比较伴和不伴1q MM样本间基因表达谱的差异。 结果: ①180例患者中,男98例、女82例,中位年龄60(33~86)岁。1q发生率为51.1%(92/180),174例患者随访资料完整,其中1q组88例,无1q组86例。②1q组和无1q组伴del(1p)的发生率分别为27.8%和9.4%(χ(2)=3.71,P=0.040),伴IGH重排的发生率分别为72.2%和57.6%(χ(2)=4.09,P=0.017),差异均有统计学意义。③1q组和无1q组患者的中位无进展生存(PFS)时间分别为15.0(95% CI 15.0~22.1)、20.3(95% CI 20.7~31.2)个月,中位总生存(OS)时间分别为29.4(95% CI 28.9~38.7)、44.0(95% CI 36.4~47.6)个月,1q组较无1q组均显著缩短(P值分别为0.029、0.038),且1q为影响患者预后的独立不良因素(PFS:HR=1.910,95%CI 1.105~3.303,P=0.020;OS:HR=2.353,95%CI 1.090~5.078,P=0.029)。④伴1q患者中,Btz治疗组深度缓解率(≥非常好的部分缓解率)明显优于非Btz组(62.1%对40.0%,P=0.032),序贯auto-HSCT组较非移植组PFS期明显延长(19对13个月,P=0.048)。⑤基因表达谱分析结果显示,有1q和无1q样本的基因表达谱不同,1q上调1q21区>50%基因表达,并导致1号染色体及全基因组基因表达的异常,差异显著的基因与DNA修复和细胞周期等相关(P值均<0.001)。 结论: 1q是影响患者生存的独立预后不良因素,其常伴del(1p)和IgH重排等,Btz诱导治疗可明显提高1q患者的深度缓解率,但不改善患者的总生存,而序贯auto-HSCT巩固治疗则可能延长PFS,基因表达谱分析可能有助于解析1q高危的分子基础。.
引用
- Liu XL, Yang PY, Yu XY, et al. [Effect of 1q21 amplification on bortezomib therapeutic response and prognosis of newly diagnosed multiple myeloma patients]. Zhonghua Xue Ye Xue Za Zhi. 2018. PMID: 29779352. doi:10.3760/cma.j.issn.0253-2727.2018.05.013
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。